Oryzon Genomics SA (ORY) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Oryzon Genomics SA (Oryzon) is a clinical stage biopharmaceutical company that offers discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases. The company offers epigenetics, a regulatory system that controls gene expression without affecting the makeup of the genes themselves and provides regulation of gene transcription that has emerged as a key biological determinant of protein production and cellular differentiation. Its clinical-stage product candidates include ORY-1001, an oncology product for treating acute leukemia disease; ORY-2001 for treating Alzheimer disease, Parkinson disease and others; and ORY-3001 for treating other indications of cancer. Oryzon provides therapeutic programs and collaborative research services. The company serves patients with cancers or neurodegenerative disorders. It operates office in Spain and the US. Oryzon is headquartered in Barcelona, Spain.

Oryzon Genomics SA (ORY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 4
List of Figures 4
Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oryzon Genomics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Oryzon Genomics SA, Medical Devices Deals, 2012 to YTD 2018 9
Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deal Details 11
Equity Offering 11
Oryzon Genomics to Raise USD19.6 Million in Private Placement of Shares 11
Oryzon Genomics Raises USD0.7 Million in Private Placement of Shares upon Exercise of Warrants 13
Oryzon Genomics Raises Funds in IPO 14
Oryzon Genomics Raises USD19 Million in Private Placement of Shares 15
Oryzon Genomics SA - Key Competitors 16
Oryzon Genomics SA - Key Employees 17
Oryzon Genomics SA - Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Joint Venture 18
Recent Developments 19
Financial Announcements 19
May 09, 2018: ORYZON Reports Financial Results and Corporate Update for the 1st Quarter 2018 19
Feb 19, 2018: ORYZON Reports Financial Results and Corporate Update for the 4th Quarter and Year Ended December 31, 2017 21
Nov 07, 2017: ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2017 23
Jul 28, 2017: ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2017 25
May 09, 2017: ORYZON Reports Financial Results and Corporate Update for the 1st Quarter, 2017 27
Feb 24, 2017: ORYZON Reports Financial Results and Corporate Update for the Fourth Quarter and Year Ended December 31, 2016 29
Corporate Communications 30
Feb 19, 2018: Oryzon revamps its Board with an expert in Biomedicine and Epigenetics in the US industry 30
May 16, 2017: Oryzon announces appointment of new Chief Medical Officer and expansion of its Medical Department 31
Government and Public Interest 32
May 15, 2017: $2.6 Million in New Grants Spurs Innovation 32
Product News 35
01/30/2017: Oryzon Genomics Will Present Data on ORY-1001 at Keystone Symposia on Epigenetics and Human Disease 35
Clinical Trials 36
Jan 09, 2017: ORYZON Announces First Patient Dosed in Phase 1 Trial of the LSD1 inhibitor RG6016 in Small Cell Lung Cancer (SCLC) 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List Of Tables

List of Tables
Oryzon Genomics SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oryzon Genomics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oryzon Genomics SA, Deals By Therapy Area, 2012 to YTD 2018 8
Oryzon Genomics SA, Medical Devices Deals, 2012 to YTD 2018 9
Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Oryzon Genomics to Raise USD19.6 Million in Private Placement of Shares 11
Oryzon Genomics Raises USD0.7 Million in Private Placement of Shares upon Exercise of Warrants 13
Oryzon Genomics Raises Funds in IPO 14
Oryzon Genomics Raises USD19 Million in Private Placement of Shares 15
Oryzon Genomics SA, Key Competitors 16
Oryzon Genomics SA, Key Employees 17
Oryzon Genomics SA, Other Locations 18
Oryzon Genomics SA, Joint Venture 18

List Of Figures

List of Figures
Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Oryzon Genomics SA, Medical Devices Deals, 2012 to YTD 2018 9

Oryzon Genomics SA (ORY) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Oryzon Genomics SA (Oryzon) is a clinical stage biopharmaceutical company that offers discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases. The company offers epigenetics, a regulatory system

USD 250 View Report

Oryzon Genomics SA Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Oryzon Genomics SA Company Profile is a detailed strategic and analytical report on Oryzon Genomics SA. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Quantum Genomics SA Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Quantum Genomics SA Company Profile is a detailed strategic and analytical report on Quantum Genomics SA. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Oryzon Genomics SA Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Oryzon Genomics SA Company Profile is a detailed strategic and analytical report on Oryzon Genomics SA. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available